Lilly Tells Investors That Antisense Will Help Fuel Growth; RNAi Falls to the Wayside
Lilly Tells Investors That Antisense Will Help Fuel Growth; RNAi Falls to the Wayside
By Doug Macron
RNAi News
December 14, 2006
Although Lilly was an early mover in the RNAi space, striking a drug-discovery collaboration with Sirna Therapeutics, the big pharma has embraced antisense as a more advanced gene-silencing technology for therapeutics.
Paid subscription is required to view article.
Votes:7
Comments: 0